DV
Dividend Vision

QCLS — Q/C Technologies, Inc.

Q/C Technologies, Inc. (QCLS)

Total return is -100.0% over the past 12.6 years, 524.2 points behind SPY at 424.2%. Its deepest 1-year drawdown was 76.1%.

Q/C Technologies, Inc. is a clinical-stage pharmaceutical company developing immunometabolic treatments for autoimmune and metabolic disorders, including a small molecule candidate called Isomyosamine and a synthetic CBD derivative called Supera-CBD, while also pursuing quantum computing technology applications. The company does not currently distribute dividends. This security appeals primarily to investors with risk tolerance for early-stage biotechnology development, as the company remains in clinical stages with no approved products generating revenue.

QCLS key facts

Asset type
Stock
Asset class
Equity
Inception date
01/23/2014
Last close
$2.77
Market cap
$26,780,194
Average volume
113800.0
Beta
2.136
Payout ratio
0.0
Forward P/E
0.0
EPS
$-8.45